
IDWeek 2025
Atlanta, Georgia 19 October 2025 - 22 October 2025
Pivotal phase III trial shows Tx potential of oral carbapenem for cUTI or acute pyelonephritis
20 Nov 2025
bởiAudrey Abella
Results from the phase III PIVOT-PO study demonstrate the potential of tebipenem pivoxil hydrobromide (TBP-PI) as an effective oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI).
Pivotal phase III trial shows Tx potential of oral carbapenem for cUTI or acute pyelonephritis
20 Nov 2025
Novel RSV vaccine safe to use in solid organ transplant recipients
17 Nov 2025
bởiStephen Padilla
Two doses of mRNA-1345 respiratory syncytial virus (RSV) vaccine 50 µg administered 56 days apart do not yield any safety concerns and are well-tolerated among solid organ transplant recipients (SOTRs), according to a study presented at IDWeek 2025.
Novel RSV vaccine safe to use in solid organ transplant recipients
17 Nov 2025
Novel mRNA-based vaccine prevents flu infection in adults
17 Nov 2025
bởiStephen Padilla
The novel mRNA-based influenza vaccine mRNA-1010 has demonstrated superior efficacy over its standard-dose (SD) comparator in preventing RT-PCR–confirmed protocol-defined influenza disease in adults aged 50 years and above, reports a study presented at IDWeek 2025.



